Aktuelle Urol 2020; 51(06): 547-551
DOI: 10.1055/a-0758-9944
Übersicht
Thieme. All rights reserved. (2020) Georg Thieme Verlag KG

Antihormonelle Therapie des Prostatakarzinoms − Behandlungsindikation und kardiovaskuläres Risikoprofil − Vorteil für GnRH-Antagonisten?

Antihormonal therapy of prostate cancer – treatment indication and cardiovascular risk profile – advantage for GnRH antagonists?
Thomas Höfner
Universitätsmedizin Mainz, Klinik und Poliklinik für Urologie und Kinderurologie, Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2018 (online)

Zusammenfassung

Das Prostatakarzinom ist die häufigste urologische Tumorerkrankung des Mannes. Im lokalisierten Tumorstadium in Kombination mit der Strahlentherapie und insbesondere im fortgeschrittenen metastasierten Tumorstadium stellt die klassische antihormonelle Therapie ein wesentliches Therapieverfahren dar. Seit ca. 10 Jahren nimmt unser Wissen um das kardiovaskuläre Risiko dieser Therapie ständig zu. Die hier vorliegende Übersichtsarbeit stellt die wesentlichen Arbeiten zum kardiovaskulären Risiko der antihormonellen Therapie vor und beschreibt im Besonderen die aktuellen Daten zum kardiovaskulären Risiko beim Einsatz der GnRH-Antagonisten. Die multizentrische prospektive PRONOUNCE-Studie soll die Frage nach einem tatsächlichen Vorteil der GnRH-Antagonisten-Therapie im Vergleich zur klassischen LHRH-Analoga-Therapie im Hinblick auf kardiovaskuläre Ereignisse detaillierter beantworten. Der Artikel stellt weiterhin das Problem der heutigen antihormonellen Übertherapie trotz fehlender wissenschaftlicher Evidenz heraus und weist auf eine verbesserte Patientenselektion für den Einsatz der antihormonellen Therapie hin.

Abstract

Introduction Prostate cancer is the most common urological tumour disease in men. In the localized tumour stage in combination with radiotherapy and especially in advanced metastastic disease, classical androgen deprivation remains an essential therapy. During the last 10 years, our knowledge of the cardiovascular risk of this therapy has rapidly increased.

Material and Methods This non-systematic review highlights the current data on cardiovascular risk in the use of androgen deprivation therapy in prostate cancer.

Results Essential publications about the cardiovascular risk of antihormonal therapy are summarised in detail. In particular, the current data on the potential cardiovascular benefit when using GnRH antagonists in androgen deprivation are discussed. The article further highlights the problem of today's antihormonal overtreatment, despite the lack of scientific evidence and points out that patient selection should be improved in the future.

Conclusion The multicentre prospective PRONOUNCE study has been designed to answer the question in more detail, as to whether GnRH antagonist therapy provides benefit with respect to the cardiovascular risk as compared to classical LHRH analogue androgen deprivation therapy.

 
  • Literatur

  • 1 Kraywinkel K, Lehnert M, Bertram H. et al. Epidemiologisches Krebsregister NRW. Schwerpunktbericht 1: Prostatakrebs. 2006
  • 2 Shahinian VB, Kuo YF, Freeman JL. et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-1624
  • 3 de la Taille A. [Circumstances of prescription of hormone therapy for patients with prostate cancer]. Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2009; 19: 313-320
  • 4 Pagliarulo V, Bracarda S, Eisenberger MA. et al. Contemporary role of androgen deprivation therapy for prostate cancer. European urology 2012; 61: 11-25
  • 5 Studer UE, Collette L, Whelan P. et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). European urology 2008; 53: 941-949
  • 6 Jones CU, Hunt D, McGowan DG. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. The New England journal of medicine 2011; 365: 107-118
  • 7 Nair B, Wilt T, MacDonald R. et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. The Cochrane database of systematic reviews 2002; DOI: 10.1002/14651858.CD003506.
  • 8 Fizazi K, Tran N, Fein L. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine 2017; 377: 352-360
  • 9 James ND, de Bono JS, Spears MR. et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine 2017; 377: 338-351
  • 10 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine 2015; 373: 737-746
  • 11 James ND, Sydes MR, Clarke NW. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177
  • 12 Nguyen PL, Alibhai SM, Basaria S. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. European urology 2015; 67: 825-836
  • 13 Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24: 4448-4456
  • 14 Tsai HK, D'Amico AV, Sadetsky N. et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute 2007; 99: 1516-1524
  • 15 Bosco C, Bosnyak Z, Malmberg A. et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. European urology 2015; 68: 386-396
  • 16 D'Amico AV, Denham JW, Crook J. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25: 2420-2425
  • 17 Alibhai SM, Duong-Hua M, Sutradhar R. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27: 3452-3458
  • 18 Hu JC, Williams SB, O'Malley AJ. et al. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. European urology 2012; 61: 1119-1128
  • 19 Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. European urology 2014; 65: 704-709
  • 20 Albertsen PC, Klotz L, Tombal B. et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. European urology 2014; 65: 565-573
  • 21 Lehmann JF, Vosgerau M, Gedamke SM. Influence of cardiovascular (CV) comorbidities on the selection of hormone deprivation therapy (HDT) in the treatment of metastatic prostate cancer (mPCa). Abstract TPS392 (205757). ASCO-GU. 2018
  • 22 Kunath F, Borgmann H, Blumle A. et al. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis. BMJ open 2015; 5: e008217
  • 23 Scailteux LM, Vincendeau S, Balusson F. et al. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. European journal of cancer 2017; 77: 99-108
  • 24 George GSL-MG, Balusson F, De Coster G. et al. The risk of cardiovascular disease following GnRH agonists versus antagonists: Real-world evidence from four European countries, Poster PT088. EAU Congress Copenhagen. 2018
  • 25 Slovin SM, Mansor-Lefebrvre S, Neijber A. et al. A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). Poster TPS395 ASCO GU. 2018